Yangtze River Pharmaceutical Group (hereinafter referred to as YRPG) is a Chinese large-scale cross-region pharmaceutical group founded in 1971. Till July 2019, with a total area of over 3 million square meters, YRPG owns 14 manufacturing subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou etc. and has established R&D and production bases of innovative chemical medicine, patent traditional Chinese medicine (TCMs) and biological medicines.
4 workshops, 6 FDFs and 1 NEX had been EU GMP certified (Enalapril Maleate Tablets, Omeprazole Enteric-coated Capsules, Nifedipine Prolonged Release Tablets, Glimepiride Tablets, Sotalol Hydrochloride Tablets, Gingko Biloba Tablets and Gingko Biloba Extract). Omeprazole Capsules was exported to Germany in 2012. 79 FDFs have been exported to 25 countries/areas in Europe, Asia and Africa. From 2012 to 2018, YRPG was awarded Top 1 among Top 100 Enterprises in China Chemical Pharmaceutical Industry.
From 2014 to 2018, YRPG was awarded Top 1 among Top 100 Enterprises in China Pharmaceutical Industry.
Middle East Region (e.g. UAE); North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Categories affiliated with Yangtze River Pharmaceutical(Group) Co.,
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation